|
|
|
|
| LEADER |
01317nam a2200253 u 4500 |
| 001 |
EB002010725 |
| 003 |
EBX01000000000000001173624 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
220201 r ||| eng |
| 100 |
1 |
|
|a Palylyk-Colwell, Eugenia
|
| 245 |
0 |
0 |
|a Oral glucose gel for neonatal hypoglycemia
|h Elektronische Ressource
|b a review of clinical effectiveness, cost-effectiveness and guidelines
|c Eugenia Palylyk-Colwell, Kaitryn Campbell
|
| 250 |
|
|
|a Version 1.0
|
| 260 |
|
|
|a Ottawa
|b CADTH
|c 2018, July 04, 2018
|
| 300 |
|
|
|a 1 PDF file (47 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 700 |
1 |
|
|a Campbell, Kaitryn
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK537952
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The purpose of this report is to synthesize and critically appraise the available evidence on the clinical effectiveness, cost-effectiveness, and guidelines for the use of oral glucose gel for neonatal hypoglycemia. The terms 'glucose' and 'dextrose' are used interchangeably in this report
|